Additional file 5 of Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

Additional file 5: Table S2. Baseline characteristics of n = 65 patients with mCRPC starting treatment with abiraterone or enzalutamide.

Institutions

Publication Details

Journal
Figshare
Published
2025-01-01
DOI
https://doi.org/10.6084/m9.figshare.22618342.v2
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Additional file 5 of Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

Figshare
Prostate Cancer Treatment and Research
article

Additional file 5 of Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

article en

Abstract

Additional file 5: Table S2. Baseline characteristics of n = 65 patients with mCRPC starting treatment with abiraterone or enzalutamide.

Figshare
Heidelberg University (DE), University Hospital Augsburg (DE), University Hospital Münster (DE)
Good health and well-being
Openalex Percentile: Top 36%
Prostate Cancer Treatment and Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Additional file 5 of Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer · Figshare (2025) | TGRS Research Map | TGRS